AWARD NUMBER: W81XWH-08-1-0632

TITLE: Orai1 as New Therapeutic Target for Inhibiting Breast Tumor Metastasis

PRINCIPAL INVESTIGATOR: Xin-Yun Huang, Ph.D.

CONTRACTING ORGANIZATION: Cornell University
New York, NY 10021

REPORT DATE: September 2009

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Orai1 as New Therapeutic Target for Inhibiting Breast Tumor Metastasis

Xin-Yun Huang, Ph.D.
E-Mail: xyhuang@med.cornell.edu

Cornell University
New York, NY 10021

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for Public Release; Distribution Unlimited

The major cause of death of cancer patients is tumor metastasis, that is, the spreading of tumors from the primary site to secondary sites. Thus development of drugs targeting this spreading process is desirable. Cell migration is one of the key steps in tumor spreading. Therefore it is very likely that inhibitors of cell migration can block tumor metastasis. Orai1 and STIM1 proteins have been recently identified to be involved in calcium influx from the extracellular environment to the inside of cells. We show here that Orai1 and STIM1 are required for tumor cell migration, invasion and tumor metastasis. Hence, Orai1 and STIM1 are potential targets for therapeutic intervention to inhibit tumor metastasis.

Subject Terms:
tumor metastasis, cell migration, signal transduction, calcium influx
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>5-17</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>18</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>18</td>
</tr>
<tr>
<td>Conclusion</td>
<td>18</td>
</tr>
<tr>
<td>References</td>
<td>19-21</td>
</tr>
<tr>
<td>Appendices</td>
<td>22-31</td>
</tr>
</tbody>
</table>
Huang, Xin-Yun

**Orail1 as New Therapeutic Target for Inhibiting Breast Tumor Metastasis**

1. **INTRODUCTION**

Despite the significant improvement in both diagnostic and therapeutic modalities for the treatment of cancer patients, metastasis still consists the major cause of mortality being responsible for ~90% of all cancer deaths (1, 2). Metastasis is the multi-step process wherein a primary tumor spreads from its initial site to secondary tissues/organs (3, 4). To disseminate from primary tumors and establish secondary tumors, cancer cells would have to succeed in migration/invasion, infiltration into circulation, survival in the circulation, penetrating through capillary endothelia and proliferating to form secondary tumors in distant organs. Failure at any of these steps could block the entire metastatic process. Since tumor spreading is responsible for the majority of deaths of cancer patients, development of therapeutic agents that inhibit tumor metastasis is very desirable. Such agents could be effective in restraining new tumor formation when earlier therapy or surgery has failed, or in increasing successful containment of solid tumors in combination therapy with other agents. To achieve the goal of preventing tumor metastasis, we need a better understanding of the molecular components involved in tumor metastasis.

One of the critical steps during tumor metastasis is tumor cell invasion and migration, which are responsible for the entry of tumor cells into lymphatic and blood vessels, as well as the extravasation of tumor cells into the secondary organs (5, 6). Cell migration is a sequential and interrelated multi-step process (7). It involves the formation of lamellipodia/membrane protrusions at the front edge, cycles of adhesion and detachment, cell body contraction, and tail retraction. Focal adhesion turnover plays a pivotal role in cell migration. Small nascent focal adhesions at the leading edge serve as traction points for the forces that move the cell body forward. On the other hand, disassembly of focal adhesions at the rear allows the retraction of the rear and net translocation of the cell in the direction of movement (8). To extravasate through capillary endothelium, cancer cells need to adhere to the endothelia cells. During migration and invasion, the adhesions between cancer cells and the extracellular matrix also undergo disassembly (8). Recently, ~20% of the cancer candidate genes in breast and colorectal cancers are found to be adhesion related genes, implying the significance of cell adhesion in cancer progression (9).

The ubiquitous second messenger Ca²⁺ is one of the critical regulators of cell migration (10). Others and we have previously shown that Ca²⁺ influx is essential for the migration of various cell types including tumor cells (11-15). In non-excitable cells, store-operated calcium (SOC) influx is the predominant Ca²⁺ entry mechanism (16, 17). Recent studies have identified two genes STIM1 (stromal-interaction molecule 1) and Orai1 (also named CRACM1) that are responsible for store-operated Ca²⁺ entry (18-22). While STIM1 serves as a Ca²⁺ sensor, Orai1 is an essential pore-forming component of the store-operated Ca²⁺ entry channel (23, 24). Co-expression of Orai1 and STIM1 is sufficient to reconstitute the SOC channel function (25-27). SOC influx controls a variety of physiological and pathological processes (28-33). However, the roles of SOC influx in tumor metastasis have not been investigated. Here we have examined the role of Orai1 and STIM1 in breast tumor cell migration, invasion and metastasis.
2. BODY

Statement of Work

Task 1. To investigate the role of Orai1 in tumor cell invasion:
   a. To examine the invasion of control siRNA, or Orai1 siRNA-treated MDA-MB-231 human breast tumor cells in matrigels
   b. To examine the effect of pharmacological inhibitors such as SKF96365 on the invasion of MDA-MB-231 cells

Task 2. To investigate the role of Orai1 in the metastasis of MDA-MB-231 human breast tumor cells in immune-deficient NOD-SCID mice:
   a. To examine the metastasis of control siRNA, or Orai1 siRNA-treated MDA-MB-231 human breast tumor cells in a mouse model
   b. To examine the effect of the pharmacological inhibitor SKF96365 on breast tumor metastasis in a mouse model

We have successfully completed all the proposed tasks.

1. Store-operated Ca\(^{2+}\) channels are critical for serum-induced cell migration

We have previously shown that Ca\(^{2+}\) influx is required for both growth factor and serum-induced fibroblast cell migration (15). To understand the molecular mechanisms, we investigated the effect on cell migration of pharmacological inhibitors for various ion channels that mediate Ca\(^{2+}\) influx (Fig. 1A). While inhibitors for voltage-gated Ca\(^{2+}\) channels (nimodipine), NMDA receptors (2-AP), or AMPA receptors (CNQX) had no effect on serum-induced fibroblast cell migration, an inhibitor for store-operated Ca\(^{2+}\) entry (SKF96365) blocked serum-induced cell migration (Fig. 1A). In these wound-healing assays, fibroblast cells were grown to confluency. A “wound” was made in the middle of the tissue culture plate with a pipet tip. In the presence of serum, cells would migrate and fill the gap after ~12 hours (15, 34-36) (Fig. 1A). The inhibitory effect of SKF96365 on cell migration was confirmed with different types of cells and by a different method of measuring cell migration. Using a Boyden chamber assay (counting cells migrating through a porous membrane), we have observed that SKF96365 inhibited the migration of human breast cancer cells (MDA-MB-231 cells) and mouse mammary tumor cells (4T1 cells) (Fig. 1B and C). To confirm that SKF96365 blocked serum-induced Ca\(^{2+}\) influx, Fluo-3 (a fluorescent Ca\(^{2+}\) indicator) based Ca\(^{2+}\) measurement was performed. Normally a serum-induced Ca\(^{2+}\) response consists of two phases, a peak phase contributed by Ca\(^{2+}\) release from intracellular Ca\(^{2+}\) stores and the plateau phase contributed by Ca\(^{2+}\) influx (37). As shown in Fig. 1D, SKF96365 decreased the amplitude of the plateau phase of the serum-induced Ca\(^{2+}\) response, without affecting the peak phase. Similar results were observed with EGTA which chelates extracellular Ca\(^{2+}\) (Fig. 1D). These pharmacological inhibitor data show that blocking Ca\(^{2+}\) influx inhibited serum-induced migration of different types of cells including breast tumor cells.

We next employed a different approach to verify the role of store-operated Ca\(^{2+}\) entry in cell migration. Recent studies have identified STIM1 and Orai1 that are responsible for store-operated Ca\(^{2+}\) entry (18-22). To examine whether STIM1 and Orai1 are important molecular components involved in cell migration, we used RNA interference to knockdown STIM1 and Orai1 in MDA-MB-231 human breast cancer cells. The successful knockdown of STIM1 or Orai1 mRNA was confirmed by western blots with anti-STIM1 or anti-Orai1 antibodies (Fig. 2A). Furthermore, the reduction of functional store-operated Ca\(^{2+}\) entry was verified by Fluo-3 based measurements (Fig. 2B). Store-operated Ca\(^{2+}\) channels are activated when internal Ca\(^{2+}\) store is empty (17). Thapsigargin was used to empty the intracellular Ca\(^{2+}\) stores in the absence of extracellular Ca\(^{2+}\). Ca\(^{2+}\) influx was then measured by addition of 2 mM extracellular Ca\(^{2+}\). Both STIM1 and Orai1 siRNAs reduced the level of Ca\(^{2+}\) influx, comparing to control siRNA (against LacZ) treated cells (Fig. 2B). Re-expression of siRNA-resistant STIM1 or Orai1 constructs restored the Ca\(^{2+}\) influx (Fig. 2C). These siRNA-resistant constructs were generated by mutating the DNA sequences targeted by siRNAs without changing the amino acid sequences. Moreover, as measured by Boyden chamber assay, serum-induced MDA-MB-231 cell migration was significantly reduced by STIM1 or Orai1 siRNA treatments (Fig. 2D). Several different coatings (including fibronectin, gelatin, and poly-D-lysine) as well as no-coating of the chamber filter membrane gave
similar results; STIM1 and Orai1 siRNAs decreased the migration of MDA-MB-231 cells by 60~85% (Fig. 2E). A second set of siRNAs for STIM1 and Orai1 gave similar results (data not shown). Re-expression of siRNA-resistant STIM1 or Orai1 constructs rescued the serum-induced cell migration (Fig. 2D). Live-cell tracking revealed that STIM1 siRNA and Orai1 siRNA treatment decreased the migration speed of MDA-MB-231 cells by ~50% (Fig. 2 F and G). In addition, overexpression of STIM1 and Orai1 in MCF-10A epithelial cells (with lower levels of endogenous STIM1 and Orai1 than in MDA-MB-231 cells) enhanced the migration of MCF-10A cells (Fig. 2H). STIM1 and Orai1 siRNA treatments did not affect the proliferation of MDA-MB-231 cells (data not shown). Hence, both pharmacological and RNAi data demonstrate that store-operated Ca2+ channels are critical for serum-induced cell migration.

2. Store-operated Ca2+ channels modulate focal adhesion turnover

Cell migration is a sequential and interrelated multistep process. It involves the formation of lamellipodia at the front edge, cycles of adhesion and detachment, cell body contraction, and tail retraction (7). To further investigate the mechanism by which Ca2+ influx controls cell migration, we studied the effect of blocking Ca2+ influx on several steps of cell migration. We found that blocking Ca2+ influx impaired the turnover of focal adhesions (Fig. 3), but had no effect on lamellipodium formation (data not shown). Focal adhesions are the cell adhesions mediated by interaction of integrin with the extracellular matrix (8, 38). Assembly and disassembly of focal adhesions are required for cell migration (8). Newly formed focal adhesions at the protrusion front of migrating cells provide anchorage points for the actin meshwork to generate traction forces that move cell body forward, while disassembly of focal adhesion in the back is necessary for the retraction of trailing tail. Focal adhesions can be visualized by immunostaining for vinculin, a major component of focal adhesions. MEF cells plated on gelatin-coated glass cover slips were treated with serum or without pharmacological inhibitors for 2 hours, fixed with 3.7% formaldehyde and then stained with vinculin antibody. In control cells, vinculin staining showed a punctuated pattern of small focal adhesions, typical of fibroblast cells (Fig. 3A). Chelation of extracellular Ca2+ with EGTA induced large peripheral adhesions while decreasing the number of adhesions in the middle of the cell (Fig. 3 A and B). Similarly, treatment of fibroblast cells with SKF96365 increased the size of focal adhesions around the peripheral of the cells (Fig. 3 A and B). Large peripheral focal adhesions were observed in 74 ± 5.7% of EGTA (n = 110) or 77 ± 8.4 % of Ni2+ (another Ca2+ influx blocker) (n = 179) treated cells and 86 ± 3.5% of SKF96365-treated cells (n = 150), while in only ~10% of control cells (n = 231) (Fig. 3B). On the other hand, treatment of fibroblast cells with inhibitors for L-type Ca2+ channels (nimodipine), NMDA receptors (2-AP), or AMPA receptors (CNQX) did not affect the size of focal adhesions (Fig. 3A). Next, to confirm these observations with a different cell type and with a different approach, we investigated focal adhesions in MDA-MB-231 human breast tumor cells treated with STIM1 and Orai1 siRNAs (Fig. 3C). While focal adhesions were small in control siRNA-treated MDA-MB-231 cells, STIM1 and Orai1 siRNA-treated cells displayed larger peripheral focal adhesions (Fig. 3C, upper panels with higher magnification). Re-expression of siRNA-resistant STIM1 or Orai1 constructs reduced the size of focal adhesions to those observed in control siRNA-treated cells (Fig. 3C). Quantitative analyses of focal adhesions showed that both the relative integrated intensity and area of focal adhesions were increased by the treatments with STIM1 or Orai1 siRNAs (Fig. 3 D and E). Comparing to control siRNA-treated cells, the size of focal adhesion in STIM1 or Orai1 siRNA treated cells was 3 times bigger and the intensity was 7 times stronger. These increases were prevented by the re-introduction of siRNA-resistant STIM1 or Orai1 constructs (Fig. 3 D and E). Since large peripheral focal adhesions are often correlated with turnover defects, these data indicate that store-operated Ca2+ channels may regulate cell migration at least partly through modulating focal adhesion turnover.

Since focal adhesion turnover includes focal adhesion assembly (formation of focal complex) and focal adhesion disassembly, we used live-cell imaging to quantify the rates of assembly and disassembly of focal adhesions (Fig. 4 A, B, C, and D). To monitor the dynamic turnover of focal adhesions, we transfected Paxillin-GFP into fibroblast cells. Paxillin is another major component of focal adhesions. From the live-cell time-lapse recordings, we observed that SKF96365 treatment prevented formation of new focal complexes at cell protrusions and also slowed the disassembly of focal adhesions. In control cells, focal adhesions assembled at a rate of 0.22 min⁻¹ and disassembled at a rate of 0.21 min⁻¹, consistent with previous reports (39) (Fig. 4 A, C, and D). In contrast, formation of new focal complexes and disassembly of focal adhesions in SKF96365-treated cells were delayed (with an assembly rate of 0.046 min⁻¹ and a disassembly rate of 0.021 min⁻¹) (Fig. 4 B, C and D). Moreover, in control cells, nascent focal adhesions generally accompanied the formation of new membrane protrusions, while in SKF96365 treated cells nascent adhesions were usually absent from new protrusions. Consequently, when treated with SKF96365, new protrusions in migrating cells failed to attach to
the substractum and thus quickly withdrew. Hence, blocking Ca\textsuperscript{2+} influx affects both the assembly and disassembly of focal adhesions, which may impair the traction force generation in migrating cells.

3. Small GTPases Ras and Rac could rescue the defects of focal adhesion turnover and cell migration induced by blocking Ca\textsuperscript{2+} influx

To further understand the mechanism by which Ca\textsuperscript{2+} influx regulates focal adhesion turnover, we investigated the participation of small GTPases since Ras and Rac are regulators of focal adhesion turnover (40, 41). We treated cells with the Ca\textsuperscript{2+} influx inhibitor SKF96365, and this treatment induced large focal adhesions due to the defective focal adhesion turnover (Fig. 4E, Red: vinculin staining). Expression of constitutively active Ras(G12V) rescued this defect and led to smaller focal complexes (Fig. 4E, green labeled cells). Similarly, constitutively active Rac1(G12V) rescued the SKF96365 effect on focal adhesion turnover (Fig. 4F). Furthermore, dominant negative mutants of Ras and Rac1 induced the formation of larger focal adhesions in MDA-MB-231 cells, implying these small GTPases are required for focal adhesion turnover (data not shown). Moreover, these rescue effects could be extended to cell migration. While Orai1 and STIM1 siRNA treatment decreased the migration of MDA-MB-231 cells, expression of constitutively active Ras(G12V) rescued the migration of these siRNA-treated cells (Fig. 4G). Constitutively active Rac1(G12V) also rescued the migration defect induced by Orai1 siRNA or STIM1 siRNA treatments (Fig. 4H). In addition, Ca\textsuperscript{2+} influx (induced by ionomycin treatment) activated Rac (by ~2-fold) in MDA-MB-231 cells (Fig. 4I). These data suggest that small GTPases Ras and Rac could rescue the defects of focal adhesion turnover and cell migration induced by blocking Ca\textsuperscript{2+} influx.

4. Orai1 and STIM1 siRNAs inhibit human breast tumor metastasis in a mouse model

Tumor metastasis is a multi-step process in which tumors spread from the primary site to secondary tissues and organs. During this process, tumor cell migration and invasion are critical (5, 6). We first investigated the role of STIM1 and Orai1 in tumor cell invasion. Control siRNA, STIM1 siRNA, or Orai1 siRNA-treated MDA-MB-231 human breast tumor cells were allowed to migrate through matrigels. As shown in Fig. 5A, fewer STIM1 or Orai1 siRNA-treated MDA-MB-231 cells than control siRNA-treated tumor cells invaded the matrigel. Re-expression of siRNA-resistant STIM1 or Orai1 constructs rescued the invasion of the STIM1 or Orai1 siRNA-treated cells (Fig. 5A). Furthermore, blocking Ca\textsuperscript{2+} influx with EGTA, Ni\textsuperscript{2+}, or SKF96365 similarly decreased the number of MDA-MB-231 tumor cells invading the matrigel (Fig. 5B). Moreover, expression of STIM1 and Orai1 in MCF-10A epithelial cells enhanced the invasion of these cells (Fig. 5C). These results suggest that STIM1 and Orai1 are needed for tumor cell invasion.

To extend these studies to an animal model, we studied the metastasis of MDA-MB-231 human breast tumor cells in immune-deficient NOD-SCID mice. We used a recently developed triple-modality reporter which encodes a fusion protein consisting of thymidine kinase, GFP and luciferase (42, 43). In these xenograft experiments, MDA-MB-231 tumor cells expressing the GFP and luciferase reporter gene were injected into immunodeficient mice through the tail vein (42, 43). Luciferase-based, noninvasive bioluminescence imaging was used to monitor the presence of tumor cells. Most of these tumor cells became trapped in the capillaries of the lungs shortly after injection (due to size restrictions imposed by mouse capillaries, human tumor cells are rarely able to pass from the arterial to the venous system (or vice versa) by way of the lung) (44) (Fig. 5D, Day 0). A substantial attenuation of bioluminescence signal was observed within the first day, indicating that cells that failed to metastasize were not able to survive (Fig. 5 D and E). Progressively increasing signals after Day 8 in mice with control siRNA-treated (stably expressing siRNA) tumor cells indicated that cells had succeeded in metastasizing and proliferating (Fig. 5 D and E). Strikingly, the presence of STIM1 siRNA or Orai1 siRNA treated cells (stably expressing siRNAs) in the lung was much less than control siRNA-treated cells at Day 1, and practically undetectable after Day 8 (Fig. 5 D and E). Therefore, STIM1 and Orai1 siRNAs significantly inhibited breast tumor metastasis.

To further confirm the defective tumor metastasis, we performed histological analyses of the lung tissues from xenografted mice (Fig. 6). Lung tissues from xenografted mice were isolated and sectioned. Hematoxylin and eosin (H&E) staining showed normal structure of the lungs from uninjected mice (without tumors) and from mice injected with STIM1 or Orai1 siRNA-treated MDA-MB-231 tumor cells (Fig. 6). In contrast, lung tissues from mice injected with control siRNA-treated tumor cells were heavily infiltrated by metastasized human breast tumor cells (Fig. 6). The identity of tumor cells in the lung tissue was confirmed by GFP fluorescence since the injected MDA-MB-231 tumor cells were labeled with GFP (Fig. 6). These results demonstrate that STIM1 and Orai1 are critical for breast tumor metastasis in a mouse model.

5. Store-operated channel blocker SKF96365 inhibits breast tumor metastasis in mouse models
We further investigated whether the pharmacological inhibitor SKF96365 could be used as a tumor metastasis inhibitor in a mouse model. We first examined the lung metastasis of 4T1 mouse mammary tumor cells in mice with or without treatment with SKF96365. The mouse 4T1 tumor closely mimics human breast cancer in its anatomical site, immunogenicity, growth characteristics, and metastatic properties (45, 46). From the mammary gland, the 4T1 tumor spontaneously metastasizes to a variety of target organs including the lung, bone, brain, and liver. Seven days after implantation of 4T1 tumor cells in the mammary glands of BALB/c mice, we injected the mice with control saline PBS or SKF96365 (daily at 10 mg/kg). After 20 days, the mice were sacrificed and examined for metastasis to the lung (46). Whereas mice injected with the control saline showed large numbers of metastasized 4T1 cells in the lung, the number of metastasized 4T1 cells in the lungs of mice treated with SKF96365 was reduced by ~80% (Fig. 7A). These results demonstrate that SKF96365 is a potent inhibitor of 4T1 tumor cell metastasis from the mammary gland to the lung.

The anti-metastatic effect of the store-operated channel blocker SKF96365 was next examined in a xenograft mouse model with human breast tumor MDA-MB-231 cells. After tail-vein injection of the tumor cells, the NOD-SCID mice were daily administered (i.p.) with 10 mg/kg SKF96365 for 4 weeks. The metastasis of tumor cells to the lung was significantly inhibited after one week of SKF96365 treatment (Fig. 7, B and C). More importantly, even two weeks after the withdrawal of SKF96365 (at the fourth week), no increase of metastasis was observed (Fig. 7B). Therefore, SKF96365 is an effective inhibitor of breast tumor metastasis in mouse models.
FIGURE LEGENDS

Figure 1. Ca\(^{2+}\) influx are required for serum-induced cell migration. (A) Wound-healing assays showed that SKF96365 (20 \(\mu M\)) inhibited the migration of MEF cells. Nimodipine (20 \(\mu M\)), DL-2-amino-5-phosphonomonopentanoic acid (DL-2-AP) (1 mM), and CNQX (10 \(\mu M\)) had no effect on MEF cell migration. (B) Boyden chamber assay showed that SKF96365 (10 \(\mu M\)) decreased serum-induced migration of MDA-MB-231 human breast tumor cells. (C) Boyden chamber assay showed that SKF96365 (10 \(\mu M\)) decreased the migration of 4T1 mouse mammary tumor cells induced by serum. (D) Fluo-3 Ca\(^{2+}\) imaging showed that SKF96365 (10 \(\mu M\)) and EGTA (2 mM) treatments decreased serum-induced Ca\(^{2+}\) influx in MEF cells. Data are either representative of three similar experiments or shown as mean \pm s.d. of five experiments. The scale bar represents 100 \(\mu m\).

Figure 2. STIM1 and Orai1 are required for serum-induced cell migration. (A) Western blots showed that STIM1 siRNA and Orai1 siRNA decreased the protein levels of STIM1 and Orai1, respectively, in MDA-MB-231 cells. 100 \(\mu g\) of total cellular protein was loaded onto each lane. (B) Fluo-3 Ca\(^{2+}\) measurement showed that STIM1 siRNA and Orai1 siRNA decreased the store-operated Ca\(^{2+}\) influx in MDA-MB-231 cells. TG: thapsigargin. (C) Fluo-3 Ca\(^{2+}\) measurement showed that siRNA-resistant STIM1 or Orai1 constructs restored Ca\(^{2+}\) influx in STIM1 or Orai1 siRNA treated cells, respectively. (D) STIM1 siRNA and Orai1 siRNA decreased serum-induced migration of MDA-MB-231 cells. (E) STIM1 siRNA and Orai1 siRNA decreased serum-induced migration of MDA-MB-231 cells in Boyden chamber assays with different coatings (including fibronectin, gelatin, and poly-D-lysine) as well as no-coating of the chamber filter membrane. (F) Migrating traces, obtained by tracking the movement of cells over a course of 2 hours, of MDA-MB-231 cells expressing control siRNA or STIM1 and Orai1 siRNAs. (G) Scattered dot plot of cell migration speed obtained by cell tracking. 19 control siRNA-treated cells and 14 STIM1 and Orai1 siRNA-treated cells were tracked. Bar, mean \pm S.E. \(p < 2 \times 10^{-3}\), as calculated by one tail Student’s \(t\)-test. (H) Overexpression of STIM1 and Orai1 in MCF-10A epithelial cells enhanced the invasion of MCF-10A cells. Data are either representative of three similar experiments or shown as mean \pm s.d. of five experiments. *, \(p < 0.05\).

Figure 3. Blocking Ca\(^{2+}\) influx impairs focal adhesion turnover. (A) Vinculin staining of fibroblast cells. Treatment with EGTA (2 mM) or SKF96365 (20 \(\mu M\)) induced large peripheral focal adhesions in MEF cells. Nimodipine (20 \(\mu M\)), DL-2-AP (1 mM), or CNQX (10 \(\mu M\)) had no effect. SOC: store-operated Ca\(^{2+}\) entry channel. Scale bar: 10 \(\mu m\). (B) Quantification of cells with large peripheral focal adhesions. 1 mM Ni\(^{2+}\), 2 mM EGTA, or 20 \(\mu M\) SKF96365 were used. Data are shown as mean \pm s.d. of three experiments. (C) Vinculin staining of MDA-MB-231 cells. STIM1 siRNA and Orai1 siRNA induced large peripheral focal adhesions in MDA-MB-231 cells. Enlarged view (scale bar: 4 \(\mu m\)) of boxed areas is shown on top of respective panels (scale bar: 20 \(\mu m\)). (D and E) Quantification of focal adhesions. The relative integrated intensity (D) and the area (E) of focal adhesions under different conditions were quantified. Data are expressed as mean \pm SE. 600 to 1000 focal adhesions in 10-15 cells were quantified for each type of cell. *, \(p < 10^{-5}\).

Figure 4. Blocking Ca\(^{2+}\) influx impair the assembly and disassembly of focal adhesions. (A and B) Live cell imaging of paxillin-GFP transfected MEF cells in the absence (A) or presence (B) of SKF96365. Scale bar: 10 \(\mu m\). (C and D) Quantification of the assembly (C) and disassembly (D) of focal adhesions from live-cell time-lapse recordings of paxillin-GFP transfected cells. (E and F) MEF cells were infected with retroviruses pBMN-H-Ras(G12V)-IRES-GFP (E) or pBMN-Rac1(G12V)-IRES-GFP (F). These cells were then treated with 10 \(\mu M\) SKF96365 for 2 hours and stained with anti-vinculin antibody. Red: vinculin staining. Green: GFP. Scale bar: 10 \(\mu m\). (G and H) MDA-MB-231 cells were infected with retroviruses pBMN-H-Ras(G12V)-IRES-GFP (G) or pBMN-Rac1(G12V)-IRES-GFP (H). Some of these cells were then treated with Orai1 and/or STIM1 siRNAs. Cells were then used for Boyden chamber assay. (I) Activation of Rac by Ca\(^{2+}\) influx. Active Rac (Rac-GTP) proteins were precipitated with the Rac-binding domain of PAK (GST-PBD). Western blots were performed with anti-Rac antibody. Lane 1, starved MDA-MB-231 cells; Lane 2, starved MDA-MB-231 cells treated with 500 nM ionomycin for 30 minutes. Data are representative of three similar experiments or shown as mean \pm s.d. of three experiments. *, \(p < 0.05\).

Figure 5. STIM1 and Orai1 are critical for tumor cell invasion and tumor metastasis. (A) STIM1 siRNA and Orai1 siRNA treatments decreased the invasion of MDA-MB-231 cells. Data are shown as mean \pm s.d. of three experiments. (B) EGTA (2 mM), Ni\(^{2+}\) (1 mM), and SKF96365 (20 \(\mu M\)) decreased the invasion of MDA-MB-231 cells. Data are shown as mean \pm s.d. of three experiments. (C) Overexpression of STIM1 and Orai1 in
MCF-10A epithelial cells enhanced the invasion. Data are shown as mean ± s.d. of three experiments. (D) Representative of bioluminescent imaging of mice injected with MDA-MB-231 cells stably expressing control siRNA (n = 7), STIM1 siRNA (n = 9), or Orai1 siRNA (n = 8). The photon flux scale is shown at the right. (E) Quantification of the bioluminescent imaging data obtained with the IVIS Imaging System (Xenogen). Data are representative of seven, eight or nine similar experiments or shown as mean ± s.d. of seven, eight or nine experiments. *, p < 0.05.

**Figure 6.** Blocking Ca\(^{2+}\) influx inhibits tumor metastasis. Histological analyses showed the staining of lung tissue sections from untreated mice, mice injected with MDA-MB-231 cells stably expressing control siRNA, mice injected with MDA-MB-231 cells stably expressing STIM1 siRNA, and mice injected with MDA-MB-231 cells stably expressing Orai1 siRNA. The top panels were stained with H&E. T: indicates tumor metastases. The bottom panels were GFP fluorescence (Green), DAPI for nuclei (Blue), and rhodamine-conjugated phalloidin for actin polymers (Red). Data are representative of three similar experiments. The scale bar represents 100 µm.

**Figure 7.** SKF96365 inhibits tumor metastasis. (A) Inhibition of mouse 4T1 mammary tumor cell metastasis to the lung by SKF96365 in a spontaneous metastasis model (n=10). (B) Inhibition of human MDA-MB-231 cell metastasis by SKF96365 in a mouse model. (C) Representative of bioluminescent imaging of mice injected with MDA-MB-231 cells treated with (n = 7) or without (control, n = 7) SKF96365. The photon flux scale is shown at the right. Data are shown as mean ± SE.
Figure 1

A

| Serum | Serum + SOC inhibitor (SKF9636) | Serum + 1-VDCC inhibitor (nimodipine) | Serum + NMDA inhibitor (2-AP) | Serum + AMPA inhibitor (CNQX) |
--- | --- | --- | --- | --- |
![Images of cell cultures for each condition]

B

| MDA-MB-231 cells | 4T1 cells |
--- | --- |
| ![Graph showing cell migration with SKF96365 and EK57365](image) | ![Graph showing cell migration with SKF96365 and EK57365](image) |

C

![Graph showing cell migration with SKF96365 and EK57365](image)

D

![Graph showing time course of fluorescence with control, SKF96365, and EK57365](image)
Figure 3

A

<table>
<thead>
<tr>
<th>Serum</th>
<th>Serum + EGTA</th>
<th>Serum + SOC inhibitor (SKF96365)</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Cells" /></td>
<td><img src="image2" alt="Cells" /></td>
<td><img src="image3" alt="Cells" /></td>
</tr>
</tbody>
</table>

Serum + L-VDCC inhibitor (nimodipine)  
Serum + NMDA inhibitor (2-AP)  
Serum + AMPA inhibitor (CNQX)

B

Cells with large focal adhesions (%)

![Bar chart](image4)

C

<table>
<thead>
<tr>
<th>control siRNA</th>
<th>STIM1 siRNA</th>
<th>Oral1 siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image5" alt="Cells" /></td>
<td><img src="image6" alt="Cells" /></td>
<td><img src="image7" alt="Cells" /></td>
</tr>
</tbody>
</table>

STIM1 siRNA + STIM1 rescue  
Oral1 siRNA + Oral1 rescue

D

Relative intensity (fluorescence)

![Bar chart](image8)

E

Area in μm²

![Bar chart](image9)
Figure 4

A

B

C

D

E

F

G

H

I

Huang, Xin-Yun
Figure 5
Figure 6

- untreated
- control siRNA
- STIM1 siRNA
- Orai1 siRNA

H&E

GFP
DAPI
actin
Figure 7

A

B

C

Colours per kg

3.9 x 10^6

2.4 x 10^6

1.6 x 10^6

8 x 10^5

0

Control

+ SKF96365

Normalized photon flux

Time (day)

0

14

28

42

Day 0

Day 1

Day 7
3. KEY RESEARCH ACCOMPLISHMENTS

- Uncovered a critical role for Orai1 in breast tumor metastasis
- Discovered the mechanism by which calcium influx controls cell migration
- Demonstrated that pharmacological inhibitors and siRNAs against Orai1 blocked breast tumor metastasis in animal models

4. REPORTABLE OUTCOMES

a. One manuscript from this work has been published in Cancer Cell. A copy of the paper is attached.


b. Dr. Shengyu Yang is in the process of looking for a faculty job.

5. LIST OF PERSONNEL RECEIVING PAY FROM THIS RESEARCH EFFORT

The following personnel who received support at some point in time while the grant was active (depending on the technical skills required by the experiments at the time):

   Shengyu Yang

6. CONCLUSION

We have shown that STIM1 and Orai1 are essential for tumor cell migration in vitro and tumor metastasis in mice. The molecular mechanism by which Ca^{2+} influx regulates cell migration is at least partly through the modulation of focal adhesion turnover. Our data demonstrate a role for store-operated Ca^{2+} entry in tumor metastasis, making them attractive targets for therapeutic intervention.

The molecular mechanism by which Ca^{2+} regulates focal adhesion turnover is not completely understood. Focal adhesions are dynamic structures under tight spatial control at the subcellular level to enable localized responses to extracellular cues. Both protein tyrosine phosphorylation and proteolysis of proteins in focal adhesions are involved in focal adhesion turnover (8). Increase of cellular Ca^{2+} could increase the activity of tyrosine kinase FAK (focal adhesion kinase) and the calcium-dependent protease calpain in focal adhesions (47-50). FAK is a critical regulator of focal adhesion turnover. In FAK-deficient fibroblast cells, decreased migration is accompanied by an increased number of focal adhesions (51, 52). One of the biochemical functions of FAK is to activate Rac through p130Cas, Crk and DOCK180/ELMO complex (53). Calpain could cleave talin at adhesion sites leading to more rapid disassembly rates through additional downstream control of paxillin, vinculin and zyxin (54). Furthermore, other Ca^{2+}-sensitive proteins such as myosin light chain kinase and calcineurin could also mediate the Ca^{2+} effect on focal adhesion turnover (55, 56). Moreover, in addition to focal adhesions, podosomes and invadopodia are also adhesion structures, and invadopodia contribute to cancer invasion (57).

Focal adhesion turnover is critical for tumor metastasis. Blocking store-operated Ca^{2+} influx slows down the focal adhesion turnover, resulting in larger focal adhesions and consequently stronger adherence. Such strong adherence could impede the fast migration of cells, including metastatic cancer cells. Therefore, agents that block store-operated Ca^{2+} channels, such as SKF96365, siRNAs for Orai1 and STIM1, or antibodies that specifically block the channel activity of SOC, are potential therapeutics for tumor metastasis.
REFERENCES


Orai1 and STIM1 Are Critical for Breast Tumor Cell Migration and Metastasis

Shengyu Yang, J. Jillian Zhang, and Xin-Yun Huang

1Department of Physiology, Weill Medical College of Cornell University, New York, NY 10065, USA
*Correspondence: xyhuang@med.cornell.edu

SUMMARY

Tumor metastasis is the primary cause of death of cancer patients. Understanding the molecular mechanisms underlying tumor metastasis will provide potential drug targets. We report here that Orai1 and STIM1, both of which are involved in store-operated calcium entry, are essential for breast tumor cell migration in vitro and tumor metastasis in mice. Reduction of Orai1 or STIM1 by RNA interference in highly metastatic human breast cancer cells or treatment with a pharmacological inhibitor of store-operated calcium channels decreased tumor metastasis in animal models. Our data demonstrate a role for Orai1 and STIM1 in tumor metastasis and suggest store-operated calcium entry channels as potential cancer therapeutic targets.

INTRODUCTION

Despite the significant improvement in both diagnostic and therapeutic modalities for the treatment of cancer patients, metastasis still represents the major cause of mortality, being responsible for ~90% of all cancer deaths (Christofori, 2006; Hanahan and Weinberg, 2000). Metastasis is the multistep process wherein a primary tumor spreads from its initial site to secondary tissues/organs (Fidler, 2003; Weiss, 2000). To disseminate from primary tumors and establish secondary tumors, cancer cells must succeed in migration/invasion, infiltration into circulation, survival in the circulation, penetrating through capillary endothelia, and proliferating to form secondary tumors in distant organs. Failure at any of these steps can block the entire metastatic process. Since tumor spreading is responsible for the majority of deaths of cancer patients, development of therapeutic agents that inhibit tumor metastasis is highly desirable. Such agents could be effective in restraining new tumor formation when earlier therapy or surgery has failed, or in increasing successful containment of solid tumors in combination therapy with other agents. To achieve the goal of preventing tumor metastasis, a better understanding of the molecular components involved in tumor metastasis is needed.

One of the critical steps during tumor metastasis is tumor cell migration and invasion, which are responsible for the entry of tumor cells into lymphatic and blood vessels as well as the extravasation of tumor cells into the secondary organs (Mareel and Leroy, 2003; Steeg, 2006). Cell migration is a sequential and interrelated multistep process involving the formation of lamellipodia/membrane protrusions at the front edge, cycles of adhesion and detachment, cell body contraction, and tail retraction (Ridley et al., 2003). Focal adhesion turnover plays a pivotal role in cell migration. Small, nascent focal adhesions at the leading edge serve as traction points for the forces that move the cell body forward. On the other hand, disassembly of focal adhesions at the rear allows the retraction of the rear and net translocation of the cell in the direction of movement (Webb et al., 2002). To extravasate through capillary endothelium, cancer cells need to adhere to endothelial cells. During migration and invasion, the adhesions between cancer cells and the extracellular matrix also undergo disassembly (Webb et al., 2002). Recently, ~20% of the cancer candidate genes in breast and colorectal cancers were found to be adhesion-related genes, implying the significance of cell adhesion in cancer progression (Sjoblom et al., 2006).

The ubiquitous second messenger Ca^{2+} is one of the critical regulators of cell migration (Pettit and Fay, 1998). We and others have previously shown that Ca^{2+} influx is essential for the migration of various cell types, including tumor cells (Komuro and Rakic, 1993; Lee et al., 1999; Marks and Maxfield, 1990; Nishiyama et al.,...
In nonexcitable cells, store-operated calcium influx is the predominant Ca\(^{2+}\) entry mechanism (Lewis, 2007; Parekh and Penner, 1997). Recent studies have identified two genes, **STIM1** (stromal interaction molecule 1) and **Orai1** (also named **CRACM1**), that are responsible for store-operated Ca\(^{2+}\) entry (Feske et al., 2006; Liou et al., 2005; Roos et al., 2005; Vig et al., 2006; Zhang et al., 2006). While STIM1 serves as a Ca\(^{2+}\) sensor, Orai1 is an essential pore-forming component of the store-operated Ca\(^{2+}\) entry channel (Prakriya et al., 2006; Yeromin et al., 2006). Coexpression of Orai1 and STIM1 is sufficient to reconstitute the store-operated calcium channel function (Mercer et al., 2006; Peinelt et al., 2006; Soboloff et al., 2006). Store-operated calcium influx controls a variety of physiological and pathological processes (Dolmetsch et al., 1998; Fanger et al., 1995; Feske et al., 2005; Lewis, 2001; Mogami et al., 1997; Yoo et al., 2000). However, the roles of store-operated calcium influx in tumor metastasis have not been investigated. Here we examined the role of Orai1 and STIM1 in breast tumor cell migration, invasion, and metastasis.

**RESULTS AND DISCUSSION**

**Store-Operated Ca\(^{2+}\) Channels Are Critical for Serum-Induced Cell Migration**

We have previously shown that Ca\(^{2+}\) influx is required for both growth factor- and serum-induced fibroblast cell migration (Yang and Huang, 2005). To understand the molecular mechanisms, we investigated the effect on cell migration of pharmacological inhibitors for various ion channels that mediate Ca\(^{2+}\) influx (Figure 1A). While inhibitors of voltage-gated Ca\(^{2+}\) channels (nimodipine), NMDA receptors (2-AP), or AMPA receptors (CNQX) had no effect on serum-induced fibroblast cell migration, an inhibitor of store-operated Ca\(^{2+}\) entry (SKF96365) blocked serum-induced cell migration (Figure 1A). In these wound-healing assays, fibroblasts were grown to confluency, and a “wound” was made in the middle of the tissue culture plate with a pipette tip. In the presence of serum, cells would migrate and fill the gap after ~12 hr (Guo et al., 2007; Shan et al., 2006; Wang et al., 2006; Yang and Huang, 2005) (Figure 1A). The inhibitory effect of SKF96365 on cell migration was confirmed with different types of cells and by a different method of measuring cell migration. Using a Boyden chamber assay (counting cells migrating through a porous membrane), we observed that SKF96365 inhibited the migration of MDA-MB-231 human breast cancer cells and 4T1 mouse mammary tumor cells (Figures 1B and 1C). To confirm that SKF96365 blocked serum-induced Ca\(^{2+}\) influx, Fluo-3 (a fluorescent Ca\(^{2+}\) indicator)-based Ca\(^{2+}\) measurement was performed. Normally, a serum-induced Ca\(^{2+}\) response consists of two phases, a peak phase contributed by Ca\(^{2+}\) release from intracellular Ca\(^{2+}\) stores and a plateau phase contributed by Ca\(^{2+}\) influx (Berridge et al., 2003). As shown in Figure 1D, SKF96365 decreased the amplitude of the plateau phase of the serum-induced Ca\(^{2+}\) response without affecting the peak phase. Similar results were observed with EGTA, which chelates extracellular Ca\(^{2+}\) (Figure 1D). These pharmacological inhibitor data show that blocking Ca\(^{2+}\) influx inhibits serum-induced migration of different types of cells, including breast tumor cells.

We next employed a different approach to verify the role of store-operated Ca\(^{2+}\) entry in cell migration. Recent studies have identified STIM1 and Orai1, which are responsible for store-operated Ca\(^{2+}\) entry (Feske et al., 2006; Liou et al., 2005; Roos et al., 2005; Vig et al., 2006; Zhang et al., 2006). To examine whether STIM1 and Orai1 are important molecular components...
involved in cell migration, we used RNA interference (RNAi) to knock down STIM1 and Orai1 in MDA-MB-231 human breast cancer cells. The successful knockdown of STIM1 or Orai1 mRNA was confirmed by western blots with anti-STIM1 or anti-Orai1 antibodies (Figure 2A). Furthermore, the reduction of functional store-operated Ca^{2+} entry was verified by Fluo-3-based measurements (Figure 2B). Store-operated Ca^{2+} channels are activated when internal Ca^{2+} stores are empty (Lewis,
Thapsigargin was used to empty the intracellular Ca\(^{2+}\) stores in the absence of extracellular Ca\(^{2+}\). Ca\(^{2+}\) influx was then measured by addition of 2 nM extracellular Ca\(^{2+}\). Both STIM1 and Orai1 siRNAs reduced the level of Ca\(^{2+}\) influx compared to control siRNA against lacZ (Figure 2B). Re-expression of siRNA-resistant STIM1 or Orai1 constructs (generated by mutating the DNA sequences targeted by siRNAs without changing the amino acid sequences) restored the Ca\(^{2+}\) influx (Figure 2C). Moreover, as measured by Boyden chamber assay, serum-induced MDA-MB-231 cell migration was significantly reduced by STIM1 or Orai1 siRNA treatments (Figure 2D). Several different coatings (including fibronectin, gelatin, and poly-D-lysine) as well as no-coating of the chamber filter membrane produced similar results; STIM1 and Orai1 siRNAs decreased the migration of MDA-MB-231 cells by 60%–85% (Figure 2E). A second set of siRNAs for STIM1 and Orai1 produced similar results (data not shown). Re-expression of siRNA-resistant STIM1 or Orai1 constructs rescued the serum-induced cell migration (Figure 2D). Live-cell tracking revealed that STIM1 siRNA and Orai1 siRNA treatment decreased the migration speed of MDA-MB-231 cells by 50% (Figures 2F and 2G). In addition, overexpression of STIM1 and Orai1 in MCF-10A epithelial cells (with lower levels of endogenous STIM1 and Orai1 than in MDA-MB-231 cells) enhanced the migration of MCF-10A cells (Figure 2H). STIM1 and Orai1 siRNA treatments did not affect the proliferation of MDA-MB-231 cells (data not shown). Hence, both pharmacological and RNAi data demonstrate that store-operated Ca\(^{2+}\) channels are critical for serum-induced cell migration.

Store-Operated Ca\(^{2+}\) Channels Modulate Focal Adhesion Turnover

To further investigate the mechanism by which Ca\(^{2+}\) influx controls cell migration, we studied the effect of blocking Ca\(^{2+}\) influx on several steps of cell migration. We found that blocking Ca\(^{2+}\) influx impaired the turnover of focal adhesions (Figure 3) but had no effect on lamellipodium formation (data not shown). Focal adhesions are the cell adhesions mediated by interaction of integrin with the extracellular matrix (Guo and Giancotti, 2004; Webb et al., 2002). Assembly and disassembly of focal adhesions are required for cell migration (Webb et al., 2002).

Newly assembled focal adhesions at the protrusion front of migrating cells provide anchorage points for the actin meshwork to generate traction forces that move the cell body forward, while disassembly of focal adhesions in the back is necessary for the retraction of the trailing tail. Focal adhesions can be visualized by immunostaining for vinculin, a major component of focal adhesions. Murine embryonic fibroblasts (MEFs) plated on gelatin-coated glass coverslips were treated with serum with or without pharmacological inhibitors for 2 hr, fixed with 3.7% formaldehyde, and then stained with vinculin antibody. In control cells, vinculin staining showed a punctate pattern of small focal adhesions, typical of fibroblasts (Figure 3A). Chelation of extracellular Ca\(^{2+}\) with EGTA induced large peripheral adhesions while decreasing the number of adhesions in the middle of the cell (Figures 3A and 3B). Similarly, treatment of fibroblasts with SKF96365 increased the size of focal adhesions around the periphery of the cells (Figures 3A and 3B). Large peripheral focal adhesions were observed in 74% ± 5.7% of cells treated with EGTA (n = 110), 77% ± 8.4% of cells treated with Ni\(^{2+}\) (another Ca\(^{2+}\) influx blocker) (n = 179), and 86% ± 3.5% of cells treated with SKF96365 (n = 150), but in only ~10% of control cells (n = 231) (Figure 3B). On the other hand, treatment of fibroblasts with inhibitors of L-type Ca\(^{2+}\) channels (nimodipine), NMDA receptors (2-AP), or AMPA receptors (CNQX) did not affect the size of focal adhesions (Figure 3A). Next, to confirm these observations with a different cell type and a different approach, we investigated focal adhesions in MDA-MB-231 human breast tumor cells treated with STIM1 and Orai1 siRNAs (Figure 3C). While focal adhesions were small in control siRNA-treated MDA-MB-231 cells, STIM1 and Orai1 siRNA-treated cells displayed larger peripheral focal adhesions (Figure 3C, upper panels with higher magnification). Re-expression of siRNA-resistant STIM1 or Orai1 constructs reduced the size of focal adhesions to those observed in control siRNA-treated cells (Figure 3C). Quantitative analyses of focal adhesions showed that both the relative integrated intensity and the area of focal adhesions were increased by treatment with STIM1 or Orai1 siRNAs (Figures 3D and 3E). Compared to control siRNA-treated cells, the size of focal adhesions in STIM1 or Orai1 siRNA-treated cells was ~3-fold larger and the intensity was 7-fold greater. These increases were prevented by the reintroduction of siRNA-resistant STIM1 or Orai1 constructs (Figures 3D and 3E). Since large peripheral focal adhesions are often correlated with turnover defects, these data indicate that store-operated Ca\(^{2+}\) channels may regulate cell migration at least partly through modulating focal adhesion turnover.

Since focal adhesion turnover includes focal adhesion assembly (formation of focal complexes) and focal adhesion disassembly, we used live-cell imaging to quantify the rates of focal adhesion assembly and disassembly (Figures 4A–4D; see also Movies S1 and S2 available online). To monitor the dynamic turnover of focal adhesions, we transfected paxillin-GFP into fibroblasts. Paxillin is another major component of focal adhesions. From the live-cell time-lapse recordings, we observed that SKF96365 treatment prevented formation of new focal complexes at cell protrusions and also slowed the disassembly of focal adhesions. In control cells, focal adhesions assembled at a rate of 0.22/min and disassembled at a rate of 0.21/min, consistent with previous reports (Webb et al., 2004) (Figures 4A, 4C, and 4D). In contrast, formation of new focal complexes and disassembly of focal adhesions in SKF96365-treated cells were delayed, with an assembly rate of 0.04/min and a disassembly rate of 0.02/min (Figures 4B–4D). Moreover, nascent focal adhesions generally accompanied the formation of new membrane protrusions in control cells, while nascent adhesions were usually absent from new protrusions in SKF96365-treated cells. Consequently, when migrating cells were treated with SKF96365, new protrusions failed to attach to the substratum and thus quickly withdrew (Movies S1 and S2). Hence, blocking Ca\(^{2+}\) influx affects both the assembly and disassembly of focal adhesions, which may impair traction force generation in migrating cells.

The Small GTPases Ras and Rac Can Rescue the Defects of Focal Adhesion Turnover and Cell Migration Induced by Blocking Ca\(^{2+}\) Influx

To further understand the mechanism by which Ca\(^{2+}\) influx regulates focal adhesion turnover, we investigated the participation of small GTPases, since Ras and Rac are regulators of focal

adhesion turnover (Ridley and Hall, 1992; Schlaepfer and Hunter, 1998). We treated cells with the Ca^{2+} influx inhibitor SKF96365, and this treatment induced large focal adhesions due to the defective focal adhesion turnover (red vinculin staining in Figure 4E). Expression of constitutively active Ras(G12V) rescued this defect and led to smaller focal complexes (green-labeled cells in Figure 4E). Similarly, constitutively active Rac1(G12V) rescued the SKF96365 effect on focal adhesion turnover (Figure 4F). Furthermore, dominant-negative Ras and Rac1 mutants induced the formation of larger focal adhesions in MDA-MB-231 cells, implying that these small GTPases are required for focal adhesion turnover (data not shown). Moreover, these rescue effects could be extended to cell migration. While Orai1 and STIM1 siRNA treatment decreased the migration of MDA-MB-231 cells, expression of constitutively active Ras(G12V) rescued the migration of these siRNA-treated cells (Figure 4G).

Figure 3. Blocking Ca^{2+} Influx Impairs Focal Adhesion Turnover

(A) Vinculin staining of fibroblasts. Treatment with EGTA (2 mM) or SKF96365 (20 μM) induced large peripheral focal adhesions in MEFs. Nimodipine (20 μM), 2-AP (1 mM), or CNQX (10 μM) had no effect. SOC: store-operated Ca^{2+} entry channel. Scale bar = 10 μm.

(B) Quantification of cells with large peripheral focal adhesions. 1 mM Ni^{2+}, 2 mM EGTA, or 20 μM SKF96365 was used for blocking Ca^{2+} influx. Data are shown as mean ± SD of three experiments.

(C) Vinculin staining of MDA-MB-231 cells. STIM1 siRNA and Orai1 siRNA induced large peripheral focal adhesions in MDA-MB-231 cells. A magnified view of the respective boxed area is shown above each main image. Scale bar = 20 μm for main images and 4 μm for magnified images.

(D and E) Quantification of focal adhesions. The relative integrated intensity (D) and the area (E) of focal adhesions under different conditions were quantified. Data are expressed as mean ± SEM of 600–1000 focal adhesions in 10–15 cells and were quantified for each type of cell. *p < 10^{-5}.

adhesion turnover (Ridley and Hall, 1992; Schlaepfer and Hunter, 1998). We treated cells with the Ca^{2+} influx inhibitor SKF96365, and this treatment induced large focal adhesions due to the defective focal adhesion turnover (red vinculin staining in Figure 4E). Expression of constitutively active Ras(G12V) rescued this defect and led to smaller focal complexes (green-labeled cells in Figure 4E). Similarly, constitutively active Rac1(G12V) rescued the SKF96365 effect on focal adhesion turnover (Figure 4F). Furthermore, dominant-negative Ras and Rac1 mutants induced the formation of larger focal adhesions in MDA-MB-231 cells, implying that these small GTPases are required for focal adhesion turnover (data not shown). Moreover, these rescue effects could be extended to cell migration. While Orai1 and STIM1 siRNA treatment decreased the migration of MDA-MB-231 cells, expression of constitutively active Ras(G12V) rescued the migration of these siRNA-treated cells (Figure 4G).
Constitutively active Rac1(G12V) also rescued the migration defect induced by Orai1 siRNA or STIM1 siRNA treatments (Figure 4H). In addition, Ca$^{2+}$ influx (induced by ionomycin treatment) activated Rac by ∼2-fold in MDA-MB-231 cells (Figure 4I). These data suggest that the small GTPases Ras and Rac can rescue the defects of focal adhesion turnover and cell migration induced by blocking Ca$^{2+}$ influx.

Orai1 and STIM1 siRNAs Inhibit Human Breast Tumor Metastasis in a Mouse Model

During the multistep process of tumor metastasis, tumor cell migration and invasion are critical (Mareel and Leroy, 2003; Steeg, 2006). We first investigated the role of STIM1 and Orai1 in tumor cell invasion. Control siRNA-, STIM1 siRNA-, or Orai1 siRNA-treated MDA-MB-231 human breast tumor cells were
allowed to migrate through Matrigel. As shown in Figure 5A, fewer STIM1 or Orai1 siRNA-treated MDA-MB-231 cells than control siRNA-treated tumor cells invaded the Matrigel. Re-expression of siRNA-resistant STIM1 or Orai1 constructs rescued the invasion of the STIM1 or Orai1 siRNA-treated cells (Figure 5A). Furthermore, blocking Ca^{2+} influx with EGTA, Ni^{2+}, or SKF96365 similarly decreased the number of MDA-MB-231 tumor cells invading the Matrigel (Figure 5B). Moreover, expression of STIM1 and Orai1 in MCF-10A epithelial cells enhanced the invasion of these cells (Figure 5C). These results suggest that STIM1 and Orai1 are needed for tumor cell invasion.

To extend these studies to an animal model, we studied the metastasis of MDA-MB-231 human breast tumor cells in immunodeficient NOD/SCID mice using a recently developed triple-modality reporter that encodes a fusion protein consisting of thymidine kinase, GFP, and luciferase (Minn et al., 2005a; Ponomarev et al., 2004). In these xenograft experiments, MDA-MB-231 tumor cells expressing the GFP and luciferase reporter gene were injected into immunodeficient mice through the tail vein (Minn et al., 2005a; Ponomarev et al., 2004). Luciferase-based noninvasive bioluminescence imaging was used to monitor the presence of tumor cells. Most of these tumor cells became trapped in the capillaries of the lungs shortly after injection (due to size restrictions imposed by mouse capillaries, human tumor cells are rarely able to pass from the arterial to the venous system or vice versa by way of the lung; Minn et al. [2005b]) (Figure 5D, day 0). A substantial attenuation of bioluminescence signal was observed within the first day, indicating that cells that failed to metastasize were not able to survive (Figures 5D and 5E). Progressively increasing signals after day 8 in mice with control siRNA-treated tumor cells stably expressing siRNA indicated that cells had succeeded in metastasizing and

Figure 5. STIM1 and Orai1 Are Critical for Tumor Cell Invasion and Metastasis
(A) STIM1 siRNA and Orai1 siRNA treatments decrease the invasion of MDA-MB-231 cells. *p < 0.05.
(B) EGTA (2 mM), Ni^{2+} (1 mM), and SKF96365 (20 μM) decrease the invasion of MDA-MB-231 cells.
(C) Overexpression of STIM1 and Orai1 in MCF-10A epithelial cells enhances invasion.
(D) Representative bioluminescent imaging of mice injected with MDA-MB-231 cells stably expressing control siRNA (n = 7), STIM1 siRNA (n = 9), or Orai1 siRNA (n = 8). The photon flux scale is shown at the right.
(E) Quantification of bioluminescent imaging data.
Data in (A)–(C) are shown as mean ± SD of three experiments; data in (D) are representative of seven, nine, or eight similar experiments; and data in (E) are shown as mean ± SD of seven, eight, or nine experiments.
proliferating (Figures 5D and 5E). Strikingly, the presence of STIM1 or Orai1 siRNA-treated cells stably expressing siRNAs in the lung was much less than control siRNA-treated cells at day 1 and practically undetectable after day 8 (Figures 5D and 5E). Therefore, STIM1 and Orai1 siRNAs significantly inhibit breast tumor metastasis.

To further confirm the defective tumor metastasis, we performed histological analyses of lung tissues from xenografted mice (Figure 6). Tissues were isolated and sectioned, and hematoxylin and eosin (H&E) staining showed normal structure of lungs from noninjected mice (without tumors) and from mice injected with STIM1 or Orai1 siRNA-treated MDA-MB-231 tumor cells (Figure 6). In contrast, lung tissues from mice injected with control siRNA-treated tumor cells were heavily infiltrated by metastasized human breast tumor cells (Figure 6). The identity of tumor cells in the lung tissue was confirmed by GFP fluorescence since the injected MDA-MB-231 tumor cells were labeled with GFP (Figure 6). These results demonstrate that STIM1 and Orai1 are critical for breast tumor metastasis in a mouse model.

**The Store-Operated Channel Blocker SKF96365 Inhibits Breast Tumor Metastasis in Mouse Models**

We further investigated whether the pharmacological inhibitor SKF96365 could be used as a tumor metastasis inhibitor in a mouse model. We first examined lung metastasis of 4T1 mouse mammary tumor cells in mice with or without treatment with SKF96365. The 4T1 mouse tumor closely mimics human breast cancer in its anatomical site, immunogenicity, growth characteristics, and metastatic properties (Pulaski and Ostrand-Rosenberg, 1998; Shan et al., 2005). From the mammary gland, the 4T1 tumor spontaneously metastasizes to a variety of target organs including lung, bone, brain, and liver. Seven days after implantation of 4T1 tumor cells in the mammary glands of BALB/c mice, we injected the mice with control PBS or SKF96365 (daily at 10 mg/kg). After 20 days, the mice were sacrificed and examined for metastasis in the lungs (Shan et al., 2005). Whereas mice injected with control PBS exhibited large numbers of metastasized 4T1 cells in the lungs, the number of metastasized 4T1 cells in the lungs of mice treated with SKF96365 was reduced by ~80% (Figure 7A). These results demonstrate that SKF96365 is a potent inhibitor of 4T1 tumor cell metastasis from the mammary gland to the lungs.

The antimetastatic effect of the store-operated channel blocker SKF96365 was next examined in a xenograft mouse model with MDA-MB-231 human breast tumor cells. After tail-vein injection of tumor cells, NOD/SCID mice were intraperitoneally administered 10 mg/kg SKF96365 daily for 4 weeks. The metastasis of tumor cells to the lungs was significantly inhibited after one week of SKF96365 treatment (Figures 7B and 7C). More importantly, even at day 42, two weeks after withdrawal of SKF96365, no increase in metastasis was observed (Figure 7B). Therefore, SKF96365 is an effective inhibitor of breast tumor metastasis in mouse models.

**Conclusion**

We have shown that STIM1 and Orai1 are essential for tumor cell migration in vitro and tumor metastasis in mice. The molecular mechanism by which Ca\(^{2+}\) influx regulates cell migration at least partly involves the modulation of focal adhesion turnover. Our data demonstrate a role for store-operated Ca\(^{2+}\) entry in tumor metastasis, making STIM1 and Orai1 attractive targets for therapeutic intervention.

The molecular mechanism by which Ca\(^{2+}\) regulates focal adhesion turnover is incompletely understood. Focal adhesions are dynamic structures under tight spatial control at the subcellular level to enable localized responses to extracellular cues. Both protein tyrosine phosphorylation and proteolysis of proteins in focal adhesions are involved in focal adhesion turnover (Webb et al., 2002). Increase of cellular Ca\(^{2+}\) could increase the activity of the tyrosine kinase FAK (focal adhesion kinase) and the calcium-dependent protease calpain in focal adhesions (Achison et al., 2001; Dourdin et al., 2001; Huttenlocher et al., 1997; Siciliano et al., 1996). FAK is a critical regulator of focal adhesion turnover. In FAK-deficient fibroblasts, decreased migration is accompanied by an increased number of focal adhesions (Illic et al., 1995; Ren et al., 2000). One of the biochemical functions of FAK is to activate Rac through p130Cas, Crk,
and the DOCK180/ELMO complex (Brugnera et al., 2002). Calpain could cleave talin at adhesion sites, leading to more rapid disassembly rates through additional downstream control of paxillin, vinculin, and zyxin (Franco et al., 2004). Furthermore, other Ca\(^{2+}\)-sensitive proteins such as myosin light-chain kinase and calcineurin could also mediate the Ca\(^{2+}\) effect on focal adhesion turnover (Eddy et al., 2000; Lawson and Maxfield, 1995).

Moreover, in addition to focal adhesions, podosomes and invadopodia are also adhesion structures, and invadopodia contribute to cancer invasion (Linder, 2007).

Focal adhesion turnover is critical for tumor metastasis. Blocking store-operated Ca\(^{2+}\) influx slows down focal adhesion turnover, resulting in larger focal adhesions and consequently stronger adherence. Such strong adherence could impede the fast migration of cells, including metastatic cancer cells. Therefore, agents that block store-operated Ca\(^{2+}\) channels, such as SKF96365, siRNAs for Orai1 and STIM1, or antibodies that specifically block the channel activity of store-operated calcium, are potential therapeutics for tumor metastasis.

**EXPERIMENTAL PROCEDURES**

**Cell Lines**

MDA-MB-231 cells; GPG29 retrovirus packaging cells; and the TGL reporter construct encoding herpes simplex virus thymidine kinase 1, green fluorescent protein (GFP), and firefly luciferase were gifts from the laboratories of J. Massagué and V. Ponomarev at Memorial Sloan-Kettering Cancer Center. MEFs were derived from day 14 mouse embryos. Cells were grown in high-glucose DMEM with 10% fetal bovine serum. For bioluminescence labeling, MEFs or MDA-MB-231 cells were incubated with retroviruses in growth medium supplemented with 8 \(\mu\)g/ml polybrene at 37°C for 3 hr. Cells were further cultured for 48 hr before being used for cell migration or focal adhesion staining.

**Calcium Assay**

Calcium assays were performed as described previously (Cvejić et al., 2004; Yang and Huang, 2005). For measurement of store-operated Ca\(^{2+}\) influx, 3 mM EGTA and 2 \(\mu\)M thapsigargin were added to deplete internal calcium stores. Ca\(^{2+}\) influx was induced by subsequent addition of 2 mM Ca\(^{2+}\) (free) after store depletion.

**RNA Interference**

The siRNA constructs against human STIM1 and Orai1 were generated using the pSUPER.retro vector according to the manufacturer’s instructions (OligoEngine). The sequences used were 5’-GGCTCTGGATAACGACTC-3’ and 5’-GGCTCTGGATAACGACTC-3’.
for STIM1 and 5'-CGTGCACAATCTCAACTCG-3' for Orai1, siRNA-transfected cells were selected using puromycin and used for Ca²⁺ imaging, immunostaining, cell migration, invasion, and metastasis assays. siRNA-resistant mutants for STIM1 and Orai1 were obtained by site-directed mutation of the targeting sequences without changing amino acid sequence (from GGCTCTGGATA CAGTGCTC to GCTCTGGACACTGTGCTC for STIM1 and from CGTGCACAATCTCAACTCG to GCTGATAAATCTGATTG for Orai1). The mutants were subcloned into PLNCX2 retroviral vector, and viruses were packaged in GP293 cells. Rescue experiments were conducted either by infecting siRNA stable cell lines with rescue retrovirus or by coexpressing MDA-MB-231 cells with siRNA retrovirus and rescue retrovirus. STIM1 siRNA results were further confirmed with transient transfection of two pairs of siRNA oligos: 5'-GGAGAG CUGGACAUUUUUGATT-3' and 5'-GGGAAGACCCUAUUUACCATT-3'. Orai1 siRNA results were confirmed with stable expression of 5'-TGCCCTCTTAAAGA GATAAA-3'. For western blots, anti-Orai1 antibody was from NewEast Biosciences and anti-STIM1 antibody was from Santa Cruz Biotechnology.

**Live-Cell Time-Lapse Recording**

MEFs transiently expressing paxillin-GFP were plated on gelatin-coated glass-bottomed 35 mm tissue culture dishes overnight. Cells were maintained at 37°C and pH 7.4 throughout the observation period. Focal adhesion dynamics were quantified according to Webb et al. (2004).

**MDA-MB-231 Breast Tumor Metastasis in Mice**

All animal work was performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of Weill Medical College of Cornell University. NOD/SCID immunodeficient mice were used for experimental lung metastasis experiments. MDA-MB-231 human breast tumor cells expressing the TGL reporter were transplanted subcutaneously into the mammary gland area of mice using 0.1 ml of a single-cell suspension in PBS on day 0. Starting on day 7, when the tumors averaged ~4–5 mm in diameter, SKF63635 or control PBS was administered daily by intraperitoneal injection at 10 mg/kg per mouse until day 25. On day 28, the mice were sacrificed. This dosage regimen was well tolerated with no signs of overt toxicity. Every group included ten mice. Numbers of metastatic 4T1 cells in lungs were determined by clonal assay. In brief, lungs were removed from each mouse on day 28, finely minced, and digested in 5 ml of enzyme cocktail containing 1 mg/ml collagenase type IV for 2 hr at 37°C on a platform rocker. After incubation, samples were filtered through 70 μm nylon cell strainers and washed twice with PBS. Resulting cells were suspended and plated with a series of dilutions in 10 cm tissue culture dishes in RPMI1640 medium containing 60 μM thiguanine for clonogenic growth. Since 4T1 tumor cells are resistant to 6-thiguanine, metastasized tumor cells formed foci after 14 days, at which time they were fixed with methanol and stained with 0.03% methylene blue for counting.

**Histology**

Ten weeks after xenografting, mice were anesthetized and subsequently perfused with PBS and PBS-buffered 4% paraformaldehyde. Lungs were infiltrated with 1% low-melting agarose, processed for paraffin-embedded sectioning at 8 μm, and stained with H&E. For immunohistochemistry, infiltrated lungs were embedded in OCT medium and cryosectioned at 10 μm. Cryosections were counterstained with Texas red-conjugated phalloidin and DAPI to reveal actin and nuclei.

**SUPPLEMENTAL DATA**

The Supplemental Data include two movies and can be found with this article online at http://www.cancer.cell.org/supplemental/S1535-6108(08)00438-8.

**ACKNOWLEDGMENTS**

We thank D. Webb for the paxillin-GFP plasmid, J. Massagué for MDA-MB-231 cells, V. Ponomarev for the TGL reporter plasmid, G. Gupta for help with bioluminescent imaging, and J. Hou for assistance with histological staining. We are grateful to T. Maack, L. Palmer, M. Zhu, and members of our laboratory for critical reading of the manuscript. This research was supported by the US Department of Defense Breast Cancer Research Program. S.Y. is a recipient of a Postdoctoral Fellowship in Breast Cancer Research from the New York State Department of Health.

**REFERENCES**


Cancer Cell 15, 124–134, February 3, 2009 ©2009 Elsevier Inc. 133
with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58, 1486–1493.


